newsfilter
← Latest News
Business Wire·

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

LUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week,